DK2301576T3 - Terapeutisk anvendelse af anti-CS1-antistoffer - Google Patents

Terapeutisk anvendelse af anti-CS1-antistoffer

Info

Publication number
DK2301576T3
DK2301576T3 DK10180748.5T DK10180748T DK2301576T3 DK 2301576 T3 DK2301576 T3 DK 2301576T3 DK 10180748 T DK10180748 T DK 10180748T DK 2301576 T3 DK2301576 T3 DK 2301576T3
Authority
DK
Denmark
Prior art keywords
antibodies
therapeutic use
therapeutic
Prior art date
Application number
DK10180748.5T
Other languages
Danish (da)
English (en)
Inventor
Nicolas F Landolfi
Gao Liu
Marna Williams
Yun J Tso
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Application granted granted Critical
Publication of DK2301576T3 publication Critical patent/DK2301576T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK10180748.5T 2004-03-29 2004-11-08 Terapeutisk anvendelse af anti-CS1-antistoffer DK2301576T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
EP04810631A EP1729803B1 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
DK2301576T3 true DK2301576T3 (da) 2012-12-10

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10180748.5T DK2301576T3 (da) 2004-03-29 2004-11-08 Terapeutisk anvendelse af anti-CS1-antistoffer

Country Status (8)

Country Link
JP (1) JP4758984B2 (enrdf_load_stackoverflow)
CY (1) CY1115003T1 (enrdf_load_stackoverflow)
DK (1) DK2301576T3 (enrdf_load_stackoverflow)
ES (1) ES2393539T3 (enrdf_load_stackoverflow)
HR (1) HRP20120975T1 (enrdf_load_stackoverflow)
IL (1) IL243687A0 (enrdf_load_stackoverflow)
PT (1) PT2301576E (enrdf_load_stackoverflow)
SI (1) SI2301576T1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138282A1 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
FI3794042T3 (fi) 2018-05-18 2024-05-31 Daiichi Sankyo Co Ltd Anti-muc1-eksatekaani-vasta-aine-lääkekonjugaatti
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof

Also Published As

Publication number Publication date
HK1099699A1 (en) 2007-08-24
ES2393539T3 (es) 2012-12-26
IL243687A0 (en) 2016-04-21
HRP20120975T1 (hr) 2013-01-31
JP4758984B2 (ja) 2011-08-31
PT2301576E (pt) 2012-12-20
HK1155670A1 (en) 2012-05-25
CY1115003T1 (el) 2016-12-14
JP2007530675A (ja) 2007-11-01
SI2301576T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
LTPA2018515I1 (lt) Antagonistiniai IL-17 antikūnai
DK1940465T3 (da) Ny anvendelse af anti-IL-1beta-antistoffer
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1720866T3 (da) Fremgangsmåde
ATE501174T1 (de) Antikörper gegen madcam
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DK1778618T3 (da) Syntese af triethylentetraminer
DK1802872T3 (da) Rörledning
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
NO20071430L (no) Anti-OX4OL antistoffer
DK1992697T3 (da) Fremstilling af TNFR-Fc
DK1639010T3 (da) Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom
DE602005012267D1 (de) N von geräten
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
NO20043305D0 (no) Preparation of lodixanol
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
DK1744781T3 (da) Behandling af infektionssygdomme
DK1812002T3 (da) Behandling af mastitis
DK2301576T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
FR2877833B1 (fr) Correcteur de lordoses
DK1730109T3 (da) Syntese af pyrrol-2-carbonitriler
FR2878601B1 (fr) Bague de traversee de cloison
SE0403119D0 (sv) Therapeutic agents
SE0400718D0 (sv) Therapeutic agents